Arrowhead Pharmaceuticals Future Growth
Future criteria checks 2/6
Arrowhead Pharmaceuticals is forecast to grow earnings and revenue by 21.8% and 32.9% per annum respectively. EPS is expected to grow by 26% per annum. Return on equity is forecast to be -111% in 3 years.
Key information
21.8%
Earnings growth rate
26.0%
EPS growth rate
Biotechs earnings growth | 20.6% |
Revenue growth rate | 32.9% |
Future return on equity | -111.0% |
Analyst coverage | Good |
Last updated | 08 Mar 2024 |
Recent future growth updates
Recent updates
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
Apr 14Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?
Feb 08Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022
Jan 26Accumulate Arrowhead For Its RNAi Pipeline
Jan 17Johnson & Johnson's JNJ-3989 News Could Propel Arrowhead Stock To New All-Time Highs
Nov 03Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?
Oct 09The Partnership Effect: Arrowhead Forges Its Future
Aug 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2026 | 269 | -315 | -284 | -177 | 10 |
9/30/2025 | 181 | -300 | -255 | -206 | 15 |
9/30/2024 | 126 | -313 | -482 | -316 | 15 |
12/31/2023 | 182 | -297 | -403 | -196 | N/A |
9/30/2023 | 241 | -205 | -331 | -154 | N/A |
6/30/2023 | 256 | -181 | -343 | -197 | N/A |
3/31/2023 | 273 | -150 | -353 | -245 | N/A |
12/31/2022 | 278 | -155 | -236 | -150 | N/A |
9/30/2022 | 243 | -176 | -189 | -136 | N/A |
6/30/2022 | 250 | -154 | -120 | -91 | N/A |
3/31/2022 | 263 | -112 | -75 | -52 | N/A |
12/31/2021 | 144 | -183 | 124 | 149 | N/A |
9/30/2021 | 138 | -141 | 148 | 171 | N/A |
6/30/2021 | 108 | -126 | 167 | 184 | N/A |
3/31/2021 | 89 | -110 | 165 | 181 | N/A |
12/31/2020 | 80 | -103 | -123 | -111 | N/A |
9/30/2020 | 88 | -85 | -108 | -96 | N/A |
6/30/2020 | 124 | -24 | -89 | -71 | N/A |
3/31/2020 | 139 | 10 | -46 | -27 | N/A |
12/31/2019 | 164 | 53 | -34 | -19 | N/A |
9/30/2019 | 169 | 68 | 161 | 173 | N/A |
6/30/2019 | 137 | 46 | 152 | 157 | N/A |
3/31/2019 | 95 | 10 | 130 | 132 | N/A |
12/31/2018 | 47 | -29 | 134 | 136 | N/A |
9/30/2018 | 16 | -54 | -49 | -47 | N/A |
6/30/2018 | 14 | -54 | -55 | -54 | N/A |
3/31/2018 | 22 | -44 | -52 | -50 | N/A |
12/31/2017 | 31 | -35 | -51 | -49 | N/A |
9/30/2017 | 31 | -34 | N/A | -24 | N/A |
6/30/2017 | 23 | -46 | N/A | -25 | N/A |
3/31/2017 | 13 | -60 | N/A | -33 | N/A |
12/31/2016 | 4 | -75 | N/A | -33 | N/A |
9/30/2016 | 0 | -82 | N/A | -64 | N/A |
6/30/2016 | 0 | -84 | N/A | -66 | N/A |
3/31/2016 | 0 | -81 | N/A | -61 | N/A |
12/31/2015 | 0 | -89 | N/A | -63 | N/A |
9/30/2015 | 0 | -92 | N/A | -66 | N/A |
6/30/2015 | 0 | -90 | N/A | -65 | N/A |
3/31/2015 | 0 | -85 | N/A | -61 | N/A |
12/31/2014 | 0 | -71 | N/A | -53 | N/A |
9/30/2014 | 0 | -59 | N/A | -35 | N/A |
6/30/2014 | 0 | -50 | N/A | -30 | N/A |
3/31/2014 | 0 | -44 | N/A | -25 | N/A |
12/31/2013 | 0 | -37 | N/A | -22 | N/A |
9/30/2013 | 0 | -31 | N/A | -19 | N/A |
6/30/2013 | 0 | -23 | N/A | -18 | N/A |
3/31/2013 | 0 | -25 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARWR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARWR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARWR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARWR's revenue (32.9% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ARWR's revenue (32.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARWR is forecast to be unprofitable in 3 years.